Last $1.30 USD
Change Today -0.01 / -0.76%
Volume 139.3K
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

apricus biosciences inc (APRI) Snapshot

Open
$1.30
Previous Close
$1.31
Day High
$1.33
Day Low
$1.28
52 Week High
12/30/13 - $2.71
52 Week Low
10/13/14 - $1.12
Market Cap
56.7M
Average Volume 10 Days
240.0K
EPS TTM
$-0.28
Shares Outstanding
43.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for APRICUS BIOSCIENCES INC (APRI)

apricus biosciences inc (APRI) Related Bloomberg News

View More Bloomberg News

apricus biosciences inc (APRI) Related Businessweek News

No Related Businessweek News Found

apricus biosciences inc (APRI) Details

Apricus Biosciences, Inc., a pharmaceutical company, focuses on the development and commercialization of novel therapeutics for men’s and women’s health. The company’s lead product, Vitaros, has approved for the treatment of erectile dysfunction in Canada and Europe. It is also developing Vitaros product candidate (room temperature Vitaros) that is a proprietary stabilized dosage formulation, which can be stored at room temperature conditions. The company’s product candidate in the areas of women’s health includes Femprox, an alprostadil-based cream product candidate intended for the treatment of female sexual interest/arousal disorder that has completed an approximately 400-subject proof-of-concept study. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

21 Employees
Last Reported Date: 03/17/14
Founded in 1987

apricus biosciences inc (APRI) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $477.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $421.2K
Vice President of Commercial Development
Total Annual Compensation: $229.7K
Compensation as of Fiscal Year 2013.

apricus biosciences inc (APRI) Key Developments

Apricus Biosciences, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the fourth quarter, full year of 2014 and full year of 2015

Apricus Biosciences, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenue of $1,898,000 compared to $28,000 a year ago. Loss from continuing operations before other expense was $3,182,000 compared to $3,163,000 a year ago. Loss from continuing operations was $3,132,000 compared to $3,199,000 a year ago. Net loss was $3,113,000 compared to $2,985,000 a year ago. Basic and diluted net loss per share was $0.08 compared to $0.08 a year ago. For the nine months, the company reported total revenue of $7,352,000 compared to $2,149,000 a year ago. Loss from continuing operations before other expense was $5,480,000 compared to $13,377,000 a year ago. Loss from continuing operations was $5,189,000 compared to $14,235,000 a year ago. Net loss was $4,498,000 compared to $15,593,000 a year ago. Basic and diluted net loss per share was $0.12 compared to $0.47 a year ago. The significant increase in revenues and the reduction in net loss in the first nine months of 2014 are reflective of the continued focus by management on the primary valuation driving initiatives established for this fiscal year and into 2015. In the fourth quarter of 2014 and to a greater extent in 2015, the company expects to begin to collect initial royalty revenues from partner sales of Vitaros in Europe. These revenues will be based on sales reports received from licensee partners and will reflect sales of product in their territory multiplied by the applicable contracted double-digit royalty rates. The company expects to have net cash outflow from operations during the remainder of 2014 and during 2015 as it continues to develop room temperature Vitaros, continues a Phase 2a development program for RayVa.

Apricus Biosciences, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Apricus Biosciences, Inc. announced that they will report Q3, 2014 results at 8:05 PM, GMT Standard Time on Nov 10, 2014

Apricus Biosciences, Inc., Q3 2014 Earnings Call, Nov 10, 2014

Apricus Biosciences, Inc., Q3 2014 Earnings Call, Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APRI:US $1.30 USD -0.01

APRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $67.32 USD +0.47
GlaxoSmithKline PLC 1,465 GBp 0.00
Pfizer Inc $31.10 USD +0.63
View Industry Companies
 

Industry Analysis

APRI

Industry Average

Valuation APRI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.6x
Price/Book 4.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APRICUS BIOSCIENCES INC, please visit www.apricusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.